Fewer dollars, more sense.
David H
DH
Garfield
Aleck
A
Hercbergs
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics / Q000627:therapeutic use*; D013956:Antithyroid Agents / Q000008:administration & dosage; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008713:Methimazole / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D011441:Propylthiouracil / Q000008:administration & dosage; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D013956:Antithyroid Agents; D000068258:Bevacizumab; D008713:Methimazole; D011441:Propylthiouracil